BIO-Europe Spring® 2016: Agalimmune brings novel immune-oncology therapy from US to UK

May 12, 2016
Damian Marron, CEO of Agalimmune Ltd., speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about the company's novel immuno-oncology technology and how it might fit into the market further down the line. Agalimmune is focused on the development of treatments for patients with solid tumors. The company's lead compound, AGI-134, is a fully-synthetic alpha-Gal glycolipid immunotherapy that recruits a patient's immune system to target autologous tumor antigens, to attack the patient's own tumor cells. The company is based in the UK but it also has a lab in Massachusetts, US, where the technology originates from.
Previous Video
BIO-Europe Spring® 2016: 4SC AG's CSO outlines epigenetics strategy
BIO-Europe Spring® 2016: 4SC AG's CSO outlines epigenetics strategy

4SC AG Chief Science Officer Daniel Vitt speaks to Informa senior editor and writer Sten Stovall during the...

Next Video
BIO-Europe Spring® 2016: Where can Adocia fit in the diabetes market?
BIO-Europe Spring® 2016: Where can Adocia fit in the diabetes market?

Dr. Remi Soula, co-founder and director of business development and intellectual property at Adocia, chats ...